Broader 2026 Coverage Enhances Economics Across Multiple Care Settings
A sweeping set of CMS and Medicaid reimbursement decisions is reshaping 2026 access across neuromodulation, electrophysiology, advanced wound reconstruction, diagnostic testing, and regenerative biologics. From APC assignments and ASC approvals to national pricing and expanded Medicaid coverage, these updates strengthen commercial readiness for emerging technologies while widening patient pathways across Medicare and insured state populations.
What You Need To Know
- CMS announces multiple 2026 reimbursement upgrades across neuromodulation, EP ablation, wound reconstruction, sleep apnea therapy, and DKD diagnostics.
- Vivistim and Genio both receive APC 1580, securing ~$45K outpatient rates and stronger ASC economics.
- EP ablation codes added to the ASC-CPL, creating a new growth channel for LockeT and accelerating outpatient EP care.
- CMS sets $390.75 national reimbursement for PromarkerD and modernizes skin substitute payment pathways supporting Integra’s full portfolio.
Vivistim Paired VNS Therapy Assigned to New Technology APC 1580
MicroTransponder secured a major payment milestone as CMS assigned the Vivistim Paired VNS procedure to New Technology APC 1580, establishing a national average reimbursement of ~$45,000 for outpatient procedures starting January 1, 2026 . The payment level aligns with the resource intensity of the Vivistim implantation and is expected to stabilize hospital economics for a therapy aimed at chronic stroke recovery.
MicroTransponder leadership noted the decision underscores the therapy’s capacity to address unmet needs in upper-limb functional restoration, allowing hospitals to expand access for Medicare beneficiaries without financial strain.
Nyxoah’s Genio HGNS Implant Also Moves Into APC 1580
Nyxoah’s Genio hypoglossal nerve stimulation (HGNS) implant for obstructive sleep apnea (OSA) also received placement in APC 1580, driving a 48% reimbursement increase for hospital outpatient departments and a 58% increase for ASCs compared with 2025
Under the 2026 HOPPS and ASC Final Rule, reimbursement for CPT 64568 climbs to $45,000 in HOPDs and $42,373 in ASCs, creating a markedly stronger economic foundation for Genio’s U.S. rollout. The new ASC rate is particularly impactful for Genio’s single-incision, workflow-efficient procedure design, positioning Nyxoah to accelerate adoption across Medicare-heavy sites of service.
EP Ablation Codes Added to ASC-CPL, Opening Growth Path for LockeT
In a landmark shift for electrophysiology (EP), CMS has added key ablation codes to the ASC-Covered Procedures List beginning January 1, 2026, a structural change that expands Medicare beneficiary access to EP services outside hospital settings. The update is one of the most significant changes in EP reimbursement in more than twenty years, according to Heart Rhythm Advocates.
Catheter Precision highlighted that the change creates a major commercial opening for LockeT, its suture retention device, which supports rapid hemostasis and same-day discharge in post-ablation workflows. The shift allows ASCs to increase efficiency, lower costs, and adopt devices that support fast turnover and safe recovery
Integra LifeSciences Gains Uniform Coverage for Skin Substitutes
Integra LifeSciences welcomed broad policy updates as CMS finalized 2026 MPFS and OPPS rules that systematically support all four of its skin substitute platforms, Integra®, PriMatrix®, Cytal®, and AmnioExcel®. These products span PMA-approved, decellularized, and amniotic tissue technologies and are now aligned under a uniform reimbursement structure across care settings .
Integra leadership called the decision “unprecedented,” noting that streamlined reimbursement enhances access for complex wound reconstruction and rewards high-quality, evidence-driven platforms. The update supports expansion across the continuum of care as site-of-service diversification accelerates in 2026.
CMS Sets National Price for PromarkerD DKD Predictive Test
Proteomics International secured a major validation of its next-generation PromarkerD predictive test for diabetic kidney disease, with CMS establishing a national reimbursement price of $390.75 under the Clinical Laboratory Fee Schedule, effective January 1, 2026 .
The decision follows assignment of a dedicated PLA code (0579U) and supports the test’s U.S. rollout strategy, strengthening discussions with private payers who often benchmark CMS pricing. PromarkerD can identify at-risk type 2 diabetes patients up to four years before clinical symptoms, enabling earlier use of renal-protective therapies. With DKD costing the U.S. healthcare system over $130 billion annually, a scalable predictive tool offers significant potential for cost avoidance and population-level benefit.
Related news
CMS Sets New Medicare 2026 Rates Across Five Innovation Categories
BioStem Technologies Expands Medicaid Coverage for VENDAJE Portfolio
Outside Medicare, state-level reimbursement momentum accelerated as Florida Medicaid added VENDAJE® and VENDAJE AC® to its covered skin substitutes list. The move expands BioStem Technologies’ coverage footprint to thirteen state Medicaid programs, including large markets such as California, Texas, and Michigan .
BioStem leadership emphasized that Florida, one of the largest Medicaid populations, materially increases access for chronic wound patients and strengthens the company’s national reimbursement strategy. With over 70 million Americans on Medicaid, expanded coverage positions VENDAJE to serve a large underserved wound-care population and supports long-term commercial growth.
For media inquiries or to share perspectives on access and evidence policy, email editor@synopulse.com.
